XML 66 R51.htm IDEA: XBRL DOCUMENT v3.26.1
Segments of Business (Tables)
 12 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Information
Financial information relating to the Company’s reportable operating segments and reconciliations to the consolidated totals was as follows:
 Years Ended March 31,
(In millions)202620252024
Segment revenues (1)
North American Pharmaceutical$336,652 $304,507 $261,368 
Oncology & Multispecialty48,423 36,862 30,490 
Prescription Technology Solutions5,805 5,216 4,769 
Medical-Surgical Solutions11,507 11,380 11,309 
Other1,043 1,086 1,015 
Total revenues$403,430 $359,051 $308,951 
Other segment expense, net (2)
North American Pharmaceutical (3)
$332,994 $301,562 $259,030 
Oncology & Multispecialty (4)
47,274 36,095 29,783 
Prescription Technology Solutions (5)
4,761 4,341 3,934 
Medical-Surgical Solutions (6)
10,569 10,601 10,354 
Other (7)
453 1,032 958 
Total other expense, net$396,051 $353,631 $304,059 
Segment operating profit
North American Pharmaceutical$3,658 $2,945 $2,338 
Oncology & Multispecialty1,149 767 707 
Prescription Technology Solutions1,044 875 835 
Medical-Surgical Solutions938 779 955 
Other590 54 57 
Subtotal7,379 5,420 4,892 
Corporate expenses, net (8)
(931)(796)(851)
Interest expense(247)(265)(252)
Income before income taxes$6,201 $4,359 $3,789 
Segment depreciation and amortization (9)
North American Pharmaceutical$134 $155 $197 
Oncology & Multispecialty240 148 137 
Prescription Technology Solutions82 86 84 
Medical-Surgical Solutions96 91 82 
Other4 18 14 
Corporate173 138 121 
Total segment depreciation and amortization$729 $636 $635 
Segment expenditures for long-lived assets (10)
North American Pharmaceutical$334 $243 $159 
Oncology & Multispecialty78 88 96 
Prescription Technology Solutions4 11 31 
Medical-Surgical Solutions94 163 159 
Other10 17 13 
Corporate225 337 229 
Total segment expenditures for long-lived assets$745 $859 $687 
(1)Revenues from services on a disaggregated basis represent less than 1% of the North American Pharmaceutical segment’s total revenues, approximately 7% of the Oncology & Multispecialty segment’s total revenues, approximately 43% of the Prescription Technology Solutions segment’s total revenues, and less than 1% of the Medical-Surgical Solutions segment’s total revenues. The Company’s former Norwegian operations are included in Other. Revenues for the four reportable segments are derived in the U.S and Canada.
(2)Other segment expense, net include cost of sales, total operating expenses, and other income, net, for the Company’s reportable segments.
(3)The Company’s North American Pharmaceutical other segment expense, net includes the following:
•a credit of $210 million, a charge of $82 million, and a credit of $157 million for the years ended March 31, 2026, 2025, and 2024, respectively, related to the LIFO method of accounting for inventories. These amounts were recorded within “Cost of sales” in the Company’s Consolidated Statements of Operations;
•cash receipts for the Company’s share of antitrust legal settlements were $23 million, $444 million, and $244 million for the years ended March 31, 2026, 2025, and 2024, respectively. These gains were recorded within “Cost of sales” in the Company’s Consolidated Statements of Operations;
•a charge of $605 million for the year ended March 31, 2025 to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, “Business Acquisitions and Divestitures;”
•related to the bankruptcy of the Company’s customer Rite Aid Corporation (including certain of its subsidiaries, “Rite Aid”), the Company recognized a credit of $206 million for the year ended March 31, 2025 to reassess the previously reserved prepetition balance and a charge of $725 million for the year ended March 31, 2024 which primarily reflects the initial provision for bad debts. These were recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statements of Operations;
•restructuring charges of $59 million for the year ended March 31, 2025 for restructuring initiatives, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and
•charges of $57 million and $74 million for the years ended March 31, 2025 and 2024, respectively, related to the estimated liability for opioid-related claims, as discussed in Financial Note 17, “Commitments and Contingent Liabilities."
(4)The Company’s Oncology & Multispecialty other segment expense, net includes the following:
•charges of $96 million for the year ended March 31, 2026 related to the acquisition and integration of PRISM Vision and Core Ventures, which were recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statement of Operations;
•a net gain of $51 million for the year ended March 31, 2026 related to the sale of an investment and market decisions, which was recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statement of Operations; and
•a loss of $43 million for the year ended March 31, 2025 related to one of the Company’s equity method investments, which was recorded within “Other income, net” in the Company’s Consolidated Statement of Operations.
(5)The Company’s Prescription Technology Solutions other segment expense, net includes gains of $78 million in fiscal 2024 resulting from fair value adjustments of the Company’s contingent consideration liability related to the RxSS acquisition, which were recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statement of Operations.
(6)The Company’s Medical-Surgical Solutions other segment expense, net includes the following:
•charges of $25 million for the year ended March 31, 2026 related to the Company’s planned separation of its Medical‑Surgical Solutions segment, which were recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statement of Operations; and
•restructuring charges of $43 million and $204 million for the years ended March 31, 2026 and 2025, respectively, for restructuring initiatives, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
(7)The Company’s other segment expense, net for Other for the year ended March 31, 2026 includes a net gain of $503 million related to the sale of the Norway disposal group, as discussed in Financial Note 2, “Business Acquisitions and Divestitures.”
(8)Corporate expenses, net, includes the following:
•charges of $52 million for the year ended March 31, 2026 related to the Company’s planned separation of its Medical‑Surgical Solutions business, which were recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statement of Operations;
•a net charge of $23 million for the year ended March 31, 2026 related to the sale of our Norway disposal group as discussed in Financial Note 2, “Business Acquisitions and Divestitures;”
•a charge of $87 million for the year ended March 31, 2025 related to the termination of the U.K. pension plan as discussed in Financial Note 13, “Pension Benefits;”
•a charge of $62 million for the year ended March 31, 2025 related to the effect of accumulated other comprehensive loss components from the Canadian retail disposal group, as discussed in Financial Note 2, “Business Acquisitions and Divestitures;”
•a net gain of $101 million and a net loss of $24 million for the years ended March 31, 2025 and 2024, respectively, related to the Company’s investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 15, “Fair Value Measurements;”
•net charges of $51 million and $73 million for the years ended March 31, 2025 and 2024, respectively, related to the estimated liability for opioid-related claims, as discussed in Financial Note 17, “Commitments and Contingent Liabilities;”
•restructuring charges of $158 million, $68 million, and $64 million for the years ended March 31, 2026, 2025, and 2024, respectively, for restructuring initiatives, as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and
•charges of $11 million, $14 million, and $35 million for the years ended March 31, 2026, 2025, and 2024, respectively, for opioid-related costs, primarily litigation expenses, which were recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Consolidated Statements of Operations.
(9)Amounts primarily consist of amortization of acquired intangible assets purchased in connection with business acquisitions and capitalized software for internal use as well as depreciation and amortization of property, plant, and equipment, net.
(10)Long-lived assets consist of property, plant, and equipment, net and capitalized software.
Schedule of Long-lived Assets By Geographic Areas
Long-lived assets by geographic areas were as follows:
 March 31,
(In millions)20262025
Long-lived assets
United States$3,177 $2,877 
Foreign255 306 
Total long-lived assets$3,432 $3,183